Re the March 14 story UM Tissue Bank announces recall over testing procedures: Our company was mentioned briefly in an article about University of Miami Tissue Bank's tissue recall related to testing procedures. We are not affected by the recall and neither are our hospitals, surgeons or patients.
The statements about our company that were referenced were from a misleading Miami Herald article printed 11 years ago. We refuted the article then and continue to do so today.
RTI Biologics follows strict donor medical, behavioral and physical criteria provided by the Food and Drug Administration and the American Association of Tissue Banks.
What is important for the public to know is that since the advent of our proprietary, validated tissue-sterilization processes, BioCleanse®, Tutoplast® and Cancelle SP™, RTI has distributed more than 4 million implants with zero incidence of implant-associated infection.
While the risk of disease transmission from human tissue is low, donor screening and testing alone are not 100-percent effective. Our patented processes provide an added safeguard that not all tissue processors have.
We encourage patients and surgeons around the country to ask questions about the sterilization methods used to process tissue implants so that they can feel confident the tissue they are receiving is safe.
Our standard of quality and safety is unmatched in the industry today. We are a leader in the industry and set the standard for tissue safety. We are proud to be a flourishing company based in Florida, where our technology was developed, helping surgeons and hospitals meet the need for safe tissue that allows their patients to have renewed and productive lives.
Brian K. Hutchison, president and chief executive officer, RTI Biologics Inc., Alachua